Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06005740 · ClinicalTrials.gov registry record · Phase 1

A Phase 1, First in Human Study of TORL-4-500 in Patients With Advanced Cancer

A Phase 1 study of Advanced Solid Tumor and Hepatocellular Carcinoma, sponsored by TORL Biotherapeutics.

Recruiting
Registry status
Phase 1
Development phase
70
Enrollment target
10
Study locations

NCT06005740 is a Phase 1 study of Advanced Solid Tumor and Hepatocellular Carcinoma that is actively recruiting participants, run by TORL Biotherapeutics. The registered enrollment target is 70 participants, below the 193-participant average among 189 other Advanced Solid Tumor trials with a reported enrollment target (64% lower). The trial reports 10 study locations across 7 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06005740, a Phase 1 study of Advanced Solid Tumor and Hepatocellular Carcinoma, is actively recruiting participants, sponsored by TORL Biotherapeutics.

RECRUITING
Registry status
Phase 1
Development phase
70 participants
Enrollment target
10
Study locations

Study Summary

This first-in-human study will evaluate the safety, tolerability, pharmacokinetics, and antitumor activity of TORL-4-500 in patients with advanced cancer. For Part 1, any advanced or metastatic solid tumor malignancy will be evaluated including, for example, adrenocortical carcinoma (ACC).

Conditions Studied

Advanced Solid Tumor Hepatocellular Carcinoma

Interventions

  • DRUG TORL-4-500

Study Locations (10)

California

  • Providence Medical Foundation - Fullerton
  • UCLA - JCCC Clinical Research Unit - Los Angeles
  • Torrance Memorial Physician Network - Torrance

Florida

  • Mayo Clinic Jacksonville - Jacksonville
  • Florida Cancer Specialists Lake Nona Drug Development Unit - Orlando

Arizona

  • Mayo Clinic Phoenix - Phoenix

Minnesota

  • Mayo Clinic Rochester - Rochester

Virginia

  • Virginia Cancer Specialists - Lexington

Ontario

  • University Health Network, Princess Margaret Cancer Centre - Toronto

Quebec

  • McGill University Health Centre - Montreal

Trial Details

FieldValue
Enrollment Target 70 participants
Start Date 2023-12-04
Est. Completion 2026-10-31
Phase Phase 1

Sponsor

TORL Biotherapeutics

8 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06005740

The ClinicalTrials.gov registry entry for NCT06005740 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 70 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 193-participant average among 189 other Advanced Solid Tumor trials with a reported enrollment target (64% lower). The listed sponsor is TORL Biotherapeutics, which has 8 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Advanced Solid Tumor appearing as the primary indexed condition, and to 1 intervention - of which TORL-4-500 is the first listed.

NCT06005740 reports 10 study locations spanning 7 distinct geographic areas - top geographies include California, Florida, Arizona.

Frequently Asked Questions

What is clinical trial NCT06005740 about?

NCT06005740 is a clinical study titled "A Phase 1, First in Human Study of TORL-4-500 in Patients With Advanced Cancer". This first-in-human study will evaluate the safety, tolerability, pharmacokinetics, and antitumor activity of TORL-4-500 in patients with advanced cancer. For Part 1, any advanced or metastatic solid tumor malignancy will be evaluated including, for example, adrenocortical carcinoma (ACC).

What is the current status of trial NCT06005740?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 70 participants. The study started on 2023-12-04. Estimated completion is 2026-10-31.

What conditions does trial NCT06005740 study?

This clinical trial studies the following conditions: Advanced Solid Tumor, Hepatocellular Carcinoma.

What interventions are being tested in trial NCT06005740?

The interventions under investigation include: TORL-4-500 (DRUG).

Who is sponsoring clinical trial NCT06005740?

This trial is sponsored by TORL Biotherapeutics, which has 8 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06005740 being conducted?

This trial has 10 study locations across Arizona, California, Florida, Minnesota, Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Advanced Solid Tumor

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Advanced Solid Tumor

All registered trials for this condition

Hepatocellular Carcinoma

All registered trials for this condition

Arizona

All trials with a study site in Arizona

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.